Tyrosine kinase blockers: New hope for successful cancer therapy

Anti-Cancer Agents in Medicinal Chemistry

Volumn 9, Issue 1, 2009, Pages 66-76

  Pytel, Dariusz ^a,b   Sliwinski, Tomasz ^a   Poplawski, Tomasz ^a   Ferriola, Deborah ^c,d   Majsterek, Ireneusz ^a,e  

^a UNIVERSITY OF LODZ   (Poland)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Generation Biotech   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

ATP blockers; Cancer treatment; Drug resistance; Monoclonal antibodies; Tyrosine kinases

Indexed keywords

2 [2 METHOXY 5 (2,4,6 TRIMETHOXYSTYRYLSULFONYLMETHYL)ANILINO]PROPIONIC ACID; 3 METHYL 1,2,3 TRIAZENE; 4 (3 DIMETHYLAMINO 1 PYRROLIDINYLMETHYL) 3 TRIFLUOROMETHYL N [4 METHYL 3 [[4 (5 PYRIMIDINYL) 2 PYRIMIDINYL]AMINO]PHENYL]BENZAMIDE; 6 (2,6 DICHLOROPHENYL) 2 [3 (HYDROXYMETHYL)ANILINO] 8 METHYLPYRIDO[2,3 D]PYRIMIDIN 7(8H) ONE; BEVACIZUMAB; BOSUTINIB; CANERTINIB; CAPECITABINE; CETUXIMAB; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; DASATINIB; DORAMAPIMOD; ERLOTINIB; FORESTERONIA REFRACTA EXTRACT; GEFITINIB; HERBACEOUS AGENT; IMATINIB; LAPATINIB; LEFLUNOMIDE; NILOTINIB; PACLITAXEL; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; SL 0101; SMALL INTERFERING RNA; SORAFENIB; SUNITINIB; TRASTUZUMAB; TRIAZENE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VATALANIB; ZRCM 5; [4 [2 CYCLOPENTYL 9 (3 HYDROXYPHENETHYL)PURIN 6 YLAMINO]PHENYL]DIMETHYLPHOSPHINE OXIDE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL PROLIFERATION; CHROMOSOME TRANSLOCATION; CHRONIC MYELOID LEUKEMIA; CLEAR CELL CARCINOMA; CLINICAL TRIAL; COLORECTAL CARCINOMA; CONFORMATIONAL TRANSITION; DIARRHEA; DNA REPAIR; DRUG BIOAVAILABILITY; DRUG ERUPTION; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FORESTERONIA REFRACTA; GASTROINTESTINAL STROMAL TUMOR; GENE MUTATION; GLIOBLASTOMA; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LOADING DRUG DOSE; LUNG NON SMALL CELL CANCER; MEDICINAL PLANT; MELANOMA; METASTASIS POTENTIAL; MONOTHERAPY; MYELOPROLIFERATIVE DISORDER; NAUSEA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PANCREAS CARCINOMA; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; STRUCTURE ANALYSIS; VOMITING; CHEMISTRY; DRUG ANTAGONISM; NEOPLASM; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; TREATMENT OUTCOME;

EID: 61749085561     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152009787047752     Document Type: Review

References (125)

1. Manning, G.; White, D.; Martinez, R.; Hunter, T.; Sudarsanam, S. The protein kinase complement of the human genome. Science, 2002, 298, 1912.
2. Hanks, S. Genomic analysis of the eukaryotic protein kinase superfamily: a perspective. Genome Biol., 2003, 4, 111.
3. Heisterkamp, N.; Stam, K.; Groffen, J.; de Klein, A.; Grosveld, G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature, 1985, 315, 758.
4. Kharas, M.; Fruman, D. ABL oncogenes and phosphoinositide 3-kinase: mechanism of activation and downstream effectors. Cancer Res., 2005, 65, 2047.
5. Hannemann, J.; McManus, M.; Kabarowski, J.; Wiedemann, L. Haemopoietic transformation by the TEL/ABL oncogene. Br. J. Haematol., 1998, 102, 475.
6. Atfi, A.; Prunier, C.; Mazars, A.; Défachelles, A.; Cayre, Y.; Gespach, C.; Bourgeade, M. The oncogenic TEL/PDGFR beta fusion protein induces cell death through JNK/SAPK pathway. Oncogene, 1999, 18, 3878.
7. Ladanyi, M. The NPM/ALK gene fusion in the pathogenesis of anaplastic large cell lymphoma. Cancer Surv., 1997, 30, 59.
8. Gunby, R.; Sala, E.; Tartari, C.; Puttini, M.; Gambacorti-Passerini, C.; Mologni, L. Oncogenic fusion tyrosine kinases as molecular targets for anti-cancer therapy. Anticancer Agents Med. Chem., 2007, 7, 594.
9. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller, M.; Druker, B.; Lydon, N. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative Cancer Res., 1996, 56, 100.
10. Mahon, F.; Deininger, M.; Schultheis, B.; Chabrol, J.; Reiffers, J.; Goldman, J.; Melo, J.V. Selection and characterization of BCRABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance. Blood, 2000, 96, 1070.
11. Apperley, J.F. Part II: management of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol., 2007, 8, 1018.
12. Kantarjian, H.M.; Talpaz, M.; Giles, F.; O'Brien, S.; Cortes, J. New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance. Ann. Intern. Med., 2006, 145, 913.
13. Brady-Kalnay, S.M.; Tonks, N.K. Protein tyrosine phosphatases: from structure to function. Trends Cell Biol., 1994, 4, 73.
14. Tonks, N.K.; Yang, Q.; Guida, P.Jr. Structure, regulation, and function of protein tyrosine phosphatases. Cold Spring Harb. Symp. Quant. Biol., 1991, 56, 265.
15. Cowan-Jacob S. Structural biology of protein tyrosine kinases. Cell. Mol. Life Sci., 2006, 63, 2608.
16. Hubbard, S.R. Structural analysis of receptor tyrosine kinases. Prog. Biophys. Mol. Biol., 1999, 71, 343.
17. Hunter, T. When is a lipid kinase not a lipid kinase? When it is a protein kinase. Cell, 1995, 80, 225.
18. Matozaki, T.; Kasuga, M. Roles of protein-tyrosine phosphatases in growth factor signalling. Cell Signal, 1996, 8, 13.
19. Tonks, N.K.; Neel, B.G. From form to function: signaling by protein tyrosine phosphatases. Cell, 1996, 87, 365.
20. Druker, B.J.; Tamura, S.; Buchdunger, E.; Ohno, S.; Segal, G.M.; Fanning, S.; Zimmermann, J.; Lydon, N.B. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med., 1996, 2, 561.
21. Kolibaba, K.S.; Druker, B.J. Protein tyrosine kinases and cancer. Biochim. Biophys. Acta, 1997, 1333, F217.
22. Varmus, H.E. Viruses, genes, and cancer. I. The discovery of cellular oncogenes and their role in neoplasia. Cancer, 1985, 55, 2324.
23. Adamson, E.D. Oncogenes in development. Development, 1987, 99, 449.
24. Aman, P. Fusion oncogenes in tumor development. Semin. Cancer Biol., 2005, 15, 236.
25. Travali, S.; Koniecki, J.; Petralia, S.; Baserga, R. Oncogenes in growth and development. FASEB J., 1990, 4, 3209.
26. Heldin, C.H. Dimerization of cell surface receptors in signal transduction. Cell, 1995, 80, 213.
27. Greenfield, C.; Hiles, I.; Waterfield, M.D.; Federwisch, M.; Wollmer, A.; Blundell, T. L. McDonald, N. Epidermal growth factor binding induces a conformational change in the external domain of its receptor. EMBO J., 1989, 8, 4115.
28. Heldin, C.H.; Ernlund, A.; Rorsman, C.; Ronnstrand, L. Dimerization of B-type platelet-derived growth factor receptors occurs after ligand binding and is closely associated with receptor kinase activation. J. Biol. Chem., 1989, 264, 8905.
29. Hurwitz, D.R.; Emanuel, S.L.; Nathan, M.H.; Sarver, N.; Ullrich. A.; Felder, S.; Lax, I.; Schlessinger, J. J. Biol. Chem., 1991, 266, 22035.
30. Lax, I.; Mitra, A. K.; Ravera, C.; Hurwitz, D. R.; Rubinstein, M.; Ullrich, A.; Stroud, R. M. Schlessinger, J. EGF induces increased ligand binding affinity and dimerization of soluble epidermal growth factor (EGF) receptor extracellular domain. J. Biol. Chem. 1991, 266, 13828.
31. Yarden, Y.; Schlessinger, J. Epidermal growth factor induces rapid, reversible aggregation of the purified epidermal growth factor receptor. Biochemistry, 1987, 26, 1443.
32. Goldman, R.; Levy, R.B.; Peles, E.; Yarden, Y. Heterodimerization of the erbB-1 and erbB-2 receptors in human breast carcinoma cells: a mechanism for receptor transregulation. Biochemistry, 1990, 29, 11024.
33. Wada, T.; Qian, X.L.; Greene, M.I. Intermolecular association of the p185neu protein and EGF receptor modulates EGF receptor function. Cell, 1990, 61, 1339.
34. Cooper, J.A. Membrane-associated tyrosine kinases as molecular switches.Semin. Cell. Biol., 1994, 5, 377.
35. Ihle, J.N.; Kerr, I.M. Jaks and Stats in signaling by the cytokine receptor superfamily. Trends Genet., 1995, 11, 69.
36. Ihle, J.N.; Witthuhn, B.A.; Quelle, F.W.; Yamamoto, K.; Thierfelder, W.E.; Kreide, B.; Silvennoinen, O. Signaling by the cytokine receptor superfamily: JAKs and STATs. Trends Biochem. Sci., 1994, 19, 222.
37. Ullrich, A.; Schlessinger, J. Signal transduction by receptors with tyrosine kinase activity. Cell, 1990, 61, 203.
38. Cooper, J.A.; Gould, K.L.; Cartwright, C.A.; Hunter, T. Tyr527 is phosphorylated in pp60c-Src: implications for regulation. Science, 1986, 231, 1431.
39. Taylor, S.J.; Shalloway, D. The cell cycle and c-Src. Curr. Opin. Genet. Dev., 1993, 3, 26.
40. Young, M.A.; Gonfloni, S.; Superti-Furga, G.; Roux, B.; Kuriyan, J. Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell, 2001, 105, 115.
41. Rodrigues, G.A.; Park, M. Oncogenic activation of tyrosine kinases. Curr. Opin. Genet. Dev., 1994, 4, 15.
42. Besmer, P.; Lader, E.; George, P.C.; Bergold, P.J.; Qiu, F.H.; Zuckerman, E.E.; Hardy, W.D. A new acute transforming feline retrovirus with fms homology specifies a C-terminally truncated version of the c-fms protein that is different from SM-feline sarcoma virus v-fms protein. J. Viro, 1986, 60, 194.
43. Shu, H.K.; Pelley, R.J.; Kung, H. Tissue-specific transformation by epidermal growth factor receptor: a single point mutation within the ATP-binding pocket of the erbB product increases its intrinsic kinase activity and activates its sarcomagenic potential. J. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 9103.
44. van Daalen Wetters, T.; Hawkins, S.A.; Roussel, M.F.; Sherr, C.J. Random mutagenesis of CSF-1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain. EMBO J., 1992, 11, 551.
45. Druker, B.J.; Sawyers, C.L.; Kantarjian, H.; Resta, D.J.; Reese, S.F.; Ford. J.M.; Capdeville, R.; Talpaz, M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med., 2001, 344, 1038.
46. Bargmann, C.I.; Weinberg, R.A. Oncogenic activation of the neuencoded receptor protein by point mutation and deletion. EMBO J., 1988, 7, 2043.
47. Weiner, D.B.; Liu, J.; Cohen, J.A.; Williams, W.V.; Greene, M.I. A point mutation in the neu oncogene mimics ligand induction of receptor aggregation. Nature, 1989, 339, 230.
48. Zong, C.S.; Poon, B.; Chen, J.; Wang, L.H. Molecular and biochemical bases for activation of the transforming potential of the proto-oncogene c-ros. J. Virol., 1993, 67, 6453.
49. McDonough, S.K.; Larsen, S.; Brodey, R.S.; Stock, N.D.; Hardy, W.D. Jr. A transmissible feline fibrosarcoma of viral origin. Cancer Res., 1971, 31, 953.
50. Honma, Y.; Okabe-Kado, J.; Hozumi, M.; Uehara, Y.; Mizuno, S. Induction of erythroid differentiation of K562 human leukemic cells by herbimycin A, an inhibitor of tyrosine kinase activity. Cancer Res., 1989, 49, 331.
51. Takahashi, I.; Kobayashi, E.; Asano, K.; Yoshida, M.; Nakano, H. Staurosporine inhibits tyrosine-specific protein kinase activity of Rous sarcoma virus transforming protein p60. J. Antibiot. (Tokyo), 1987, 40, 1782.
52. Thiesing, J.T.; Ohno-Jones, S.; Kolibaba, K. S.; Druker, B. J. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood, 2000, 96, 3195.
53. Sliwkowski, M.X.; Lofgren, J.A.; Lewis, G.D.; Hotaling, T.E.; Fendly, B.M.; Fox, J.A. Nonclinical studies addressing the mechanism of action of trastuzumab (Herceptin). Semin. Oncol., 1999, 26, 60.
54. Cohen, M.H.; Williams, G.A.; Sridhara, R.; Chen, G.; Pazdur, R. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tAblets. Oncologist, 2003, 8, 303.
55. Buchdunger, E.; Zimmermann, J.; Mett, H.; Meyer, T.; Muller. M.; Druker, B.J.; Lydon, N.B. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res., 1996, 56, 100.
56. Heinrich, M.C.; Griffith, D.J.; Druker, B.J.; Wait, C.L.; Ott, K.A.; Zigler, A.J. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood, 2000, 96, 925.
57. Carroll, M.; Ohno-Jones, S.; Tamura, S.; Buchdunger, E.; Zimmermann, J.; Lydon, N. B.; Gilliland, D.G.; Druker, B.J. CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 1997, 90, 4947.
58. Fukuoka, M.; Yano, S.; Giaccone, G.; Tamura, T.; Nakagawa, K.; Douillard, J.Y.; Nishiwaki, Y.; Vansteenkiste, J.; Kudoh, S.; Rischin, D.; Eek, R.; Horai, T.; Noda, K.; Takata, I.; Smit, E.; Averbuch, S.; Macleod, A.; Feyereislova, A.; Dong, R.P.; Baselga, J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial). J. Clin. Oncol., 2003, 21, 2237
59. Ranson, M.; Hammond, L.A.; Ferry, D.; Kris, M.; Tullo, A.; Murray, P.I.; Miller, V.; Averbuch, S.; Ochs, J.; Morris, C.; Feyereislova, A.; Swaisland, H.; Rowinsky, E.K. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J. Clin. Oncol., 2002, 20, 2240.
60. Roskoski, R.Jr. The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem. Biophys. Res. Commun., 2004, 319, 1.
61. Sewell, J.M.; Macleod, K.G.; Ritchie, A.; Smyth, J.F.; Langdon, S.P. Targeting the EGF receptor in ovarian cancer with the tyrosine kinase inhibitor ZD 1839 ("Iressa"). [I Br. J. Cancer I], 2002, 86, 456.
62. Canil, C.M.; Moore, M.J.; Winquist, E.; Baetz, T.; Pollak, M.; Chi, K.N.; Berry, S.; Ernst, D.S.; Douglas, L.; Brundage, M.; Fisher, B.; McKenna, A.; Seymour, L. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J. Clin. Oncol., 2005, 23, 455.
63. Cappuzzo, F.; Finocchiaro, G.; Metro, G.; Bartolini, S.; Magrini, E.; Cancellieri, A.; Trisolini, R.; Castaldini, L.; Tallini, G.; Crino, L. Clinical experience with gefitinib: an update. Crit. Rev. Oncol. Hematol., 2006, 58, 31.
64. Ciardiello, F.; Troiani, T.; Caputo, F.; De Laurentiis, M.; Tortora, G.; Palmieri, G.; De Vita, F.; Diadema, M.R.; Orditura, M.; Colantuoni, G.; Gridelli, C.; Catalano, G.; De Placido, S.; Bianco, A.R. Phase II study of gefitinib in combination with docetaxel as firstline therapy in metastatic breast cancer. Br. J. Cancer, 2006, 94, 1604.
65. Cohen, E.E.; Rosen, F.; Stadler, W.M.; Recant, W.; Stenson, K.; Huo, D.; Vokes, E. E. Phase II trial of ZD1839 in recurrent or metastatic squamous cell carcinoma of the head and neck. J. Clin. Oncol., 2003, 21, 1980.
66. Kuo, T.; Cho, C.D.; Halsey, J.; Wakelee, H.A.; Advani, R.H.; Ford, J.M.; Fisher, G.A.; Sikic, B.I. Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer. J. Clin. Oncol., 2005, 23, 5613.
67. Schilder, R.J.; Sill, M.W.; Chen, X.; Darcy, K.M.; Decesare, S.L.; Lewandowski, G.; Lee, R.B.; Arciero, C.A.; Wu, H.; Godwin, A.K. Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study. Clin. Cancer Res., 2005, 11, 5539.
68. Moulder, S.L.; Yakes, F.M.; Muthuswamy, S.K.; Bianco, R.; Simpson, J.F.; Arteaga, C.L. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res., 2001, 61, 8887.
69. Herbst, R.S.; Prager, D.; Hermann, R.; Fehrenbacher, L.; Johnson, B.E.; Sandler, A.; Kris, M.G.; Tran, H.T.; Klein, P.; Li, X.; Ramies, D.; Johnson, D.H.; Miller, V.A. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J. Clin. Oncol., 2005, 23, 5892.
70. Perez-Soler, R. The role of erlotinib (Tarceva, OSI 774) in the treatment of non-small cell lung cancer. Clin. Lung Cancer, 2004, 6 Suppl 1, S20.
71. Tang, P.A.; Tsao, M.S.; Moore, M.J. A review of erlotinib and its clinical use. Expert. Opin. Pharmacother., 2006, 7, 177.
72. Philip, P.A.; Mahoney, M.R.; Allmer, C.; Thomas, J.; Pitot, H.C.; Kim, G.; Donehower, R.C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancer. J. Clin. Oncol., 2005, 23, 6657.
73. Philip, P.A.; Mahoney, M.R.; Allmer. C.; Thomas. J.; Pitot, H.C.; Kim, G.; Donehower, R.C.; Fitch, T.; Picus, J.; Erlichman, C. Phase II study of erlotinib in patients with advanced biliary cancer. J. Clin. Oncol. 2006, 24, 3069.
74. Meyerhardt, J.A.; Zhu, A.X.; Enzinger, P.C.; Ryan, D.P.; Clark, J.W.; Kulke, M.H.; Earle, C.C.; Vincitore, M.; Michelini, A.; Sheehan, S.; Fuchs, C.S. Phase II study of capecitabine, oxaliplatin, and erlotinib in previously treated patients with metastastic colorectal cancer. J. Clin. Oncol., 2006, 24, 1892.
75. Townsley, C.A.; Major, P.; Siu, L.L.; Dancey, J.; Chen, E.; Pond, G.R.; Nicklee, T.; Ho, J.; Hedley, D.; Tsao, M.; Moore, M.J.; Oza, A. M. Phase II study of erlotinib (OSI-774) in patients with metastatic colorectal cancer. Br. J. Cancer, 2006, 94, 1136.
76. Hainsworth, J.D.; Sosman, J.A.; Spigel, D.R.; Edwards, D.L.; Baughman, C.; Greco, A. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol., 2005, 23, 7889.
77. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Figlin, R. A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24, 16.
78. Polyzos, A. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma and various other solid tumors. J. Steroid Biochem. Mol. Biol., 2007, 108, 261.
79. Kulke, M.; Lenz, H.J.; Meropol, N.J.; Posey, J.; Ryan, D.P.; Picus, J.; Bergsland, E.; Stuart, K.; Baum, C.M.; Fuchs, C.S. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. (Meeting Abstracts) 2005, 23, 4008.
80. Wilhelm, S.; Chien, D.S. BAY 43-9006: preclinical data. Curr. Pharm. Des., 2002, 8, 2255.
81. Hotte, S.J.; Hirte, H.W. BAY 43-9006: early clinical data in patients with advanced solid malignancies. Curr. Pharm. Des., 2002, 8, 2249.
82. Kupsch, P.; Henning, B.F.; Passarge, K.; Richly, H.; Wiesemann, K.; Hilger, R.A.; Scheulen, M.E.; Christensen, O.; Brendel, E.; Schwartz, B.; Hofstra, E.; Voigtmann, R.; Seeber, S.; Strumberg, D. Results of a phase I trial of sorafenib (BAY 43-9006) in combination with oxaliplatin in patients with refractory solid tumors, including colorectal cancer. Clin. Colorectal Cancer, 2005, 5, 188.
83. Drebin, J.A.; Link, V.C.; Weinberg, R.A.; Greene, M.I. Inhibition of tumor growth by a monoclonal antibody reactive with an oncogene-encoded tumor antigen. Proc. Natl. Acad. Sci. U.S.A., 1986, 83, 9129.
84. Schindler, T.; Bornmann, W.; Pellicena, P.; Miller, W.T.; Clarkson, B.; Kuriyan, J. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science, 2000, 289, 1938.
85. Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med., 2000, 6, 443.
86. Schrag, D. The price tag on progress--chemotherapy for colorectal cancer. N. Engl. J. Med., 2004, 351, 317.
87. Gambacorti-Passerini, C.; Piazza, R.; D'Incalci, M. Bcr-Abl mutations, resistance to imatinib, and imatinib plasma levels. Blood, 2003, 102, 1933.
88. Kano, Y.; Akutsu, M.; Tsunoda, S.; Mano, H.; Sato, Y.; Honma, Y.; Furukawa, Y. In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents. Blood, 2001, 97, 1999.
89. Baran, Y.; Salas, A.; Senkal, C.E.; Gunduz, U.; Bielawski, J.; Obeid, L.M.; Ogretmen, B. Alterations of ceramide/sphingosine 1-phosphate rheostat involved in the regulation of resistance to imatinib-induced apoptosis in K562 human chronic myeloid leukemia cells. J. Biol. Chem., 2007, 282, 10922.
90. Baran, Y.; Ural, A. U.; Gunduz, U. Mechanisms of cellular resistance to imatinib in human chronic myeloid leukemia cells. Hematology, 2007, 12, 497.
91. Druker, B.J.; Talpaz, M.; Resta, D.J.; Peng, B.; Buchdunger, E.; Ford, J M.; Lydon, N.B.; Kantarjian, H.; Capdeville, R.; Ohno-Jones, S.; Sawyers, C.L. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med., 2001, 344, 1031.
92. Matheson, S.L.; McNamee, J.; Jean-Claude, B.J. Design of a chimeric 3-methyl-1,2,3-triazene with mixed receptor tyrosine kinase and DNA damaging properties: a novel tumor targeting strategy. J. Pharmacol. Exp. Ther., 2001, 296, 832.
93. Maekawa, T.; Ashihara, E.; Kimura, S. The Bcr-Abl tyrosine kinase inhibitor imatinib and promising new agents against Philadelphia chromosome-positive leukemias. Int. J. Clin. Oncol., 2007, 12, 327.
94. Yoshida, C.; Melo, J.V. Biology of chronic myeloid leukemia and possible therapeutic approaches to imatinib-resistant disease. Int. J. Hematol., 2004, 79, 420.
95. Barthe, C.; Cony-Makhoul, P.; Melo, J.V.; Mahon, J.R. Roots of clinical resistance to STI-571 cancer therapy. Science, 2001, 293, 2163.
96. Dai, Y.; Rahmani, M.; Corey, S.J.; Dent, P.; Grant, S. A Bcr/ Ablindependent, Lyn-dependent form of imatinib mesylate (STI-571) resistance is associated with altered expression of Bcl-2. J. Biol. Chem., 2004, 279, 34227.
97. Breccia, M.; Cannella, L.; Nanni, M.; Stefanizzi, C.; Alimena, G. Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy. Acta Haematol., 2007, 118, 162.
98. Jabbour, E.; Cortes, J.; Giles, F.; O'Brien, S.; Kantarijan, H. Drug evaluation: Nilotinib - a novel Bcr-Abl tyrosine kinase inhibitor for the treatment of chronic myelocytic leukemia and beyond. IDrugs 2007, 10, 468.
99. Kantarjian, H.M.; Giles, F.; Gattermann, N.; Bhalla, K.; Alimena, G.; Palandri, F.; Ossenkoppele, G.J.; Nicolini, F.E.; O'Brien, S.G.; Litzow, M.; Bhatia, R.; Cervantes, F.; Haque, A.; Shou, Y.; Resta, D.J.; Weitzman, A.; Hochhaus, A.; le Coutre, P. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosomepositive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood, 2007, 110, 3540.
100. Lynch, T.J.; Bell, D.W.; Sordella, R.; Gurubhagavatula, S.; Okimoto, R.A.; Brannigan, B.W.; Harris, P.L.; Haserlat, S.M.; Supko, J.G.; Haluska, F.G.; Louis, D.N.; Christiani, D.C.; Settleman, J.; Haber, D.A. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med., 2004, 350, 2129.
101. Paez, J.G.; Janne, P.A.; Lee, J.C.; Tracy, S.; Greulich, H.; Gabriel, S.; Herman, P.; Kaye, F.J.; Lindeman. N.; Boggon, T.J.; Naoki, K.; Sasaki. H.; Fujii, Y.; Eck, M.J.; Sellers, W.R.; Johnson, B.E.; Meyerson, M. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science, 2004, 304, 1497.
102. Tokumo, M.; Toyooka, S.; Kiura, K.; Shigematsu, H.; Tomii, K.; Aoe, M.; Ichimura, K.; Tsuda, T.; Yano, M.; Tsukuda, K.; Tabata, M.; Ueoka, H.; Tanimoto, M.; Date, H.; Gazdar, A. F.; Shimizu, N. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res., 2005, 11, 1167.
103. Pan, J.; Quintas-Cardama, A.; Manshouri, T.; Cortes, J.; Kantarjian, H.; Verstovsek, S. Sensitivity of human cells bearing oncogenic mutant kit isoforms to the novel tyrosine kinase inhibitor INNO-406. Cancer Sci., 2007, 98, 1223.
104. Deininger, M.W.; O'Brien, S.G.; Ford, J.M.; Druker, B.J. Practical management of patients with chronic myeloid leukemia receiving imatinib. J. Clin. Oncol. 2003, 21, 1637.
105. Hochhaus, A.; Kreil, S.; Corbin, A.; La Rosee, P.; Lahaye, T.; Berger, U.; Cross, N. C.; Linkesch, W.; Druker, B.J.; Hehlmann, R.; Gambacorti- Passerini, C.; Corneo, G.; D'Incalci, M. Roots of clinical resistance to STI-571 cancer therapy. Science, 2001, 293, 2163.
106. Azam, M.; Latek, R.R.; Daley, G.Q. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCRABL. Cell, 2003, 112, 831.
107. Majsterek, I.; Slupianek, A.; Hoser, G.; Skorski, T.; Blasiak, J. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance? Biochimie, 2004, 86, 53.
108. Qiu, Q.; Dudouit, F.; Matheson, S.L.; Brahimi, F.; Banerjee, R.; McNamee, J.P.; Jean-Claude, B.J. The combi-Targeting Concept: a novel 3,3-disubstituted nitrosourea with EGFR tyrosine kinase inhibitory properities. Cancer Chemother. Pharmacol., 2003, 51, 1.
109. Cameron, D.; Casey, M.; Press, M.; Lindquist, D.; Pienkowski, T.; Romieu, C.; Chan, S.; Jagiello-Gruszfeld, A.; Kaufman, B.; Crown, J.; Chan, A.; Campone, M.; Viens, P.; Davidson, N.; Gorbounova, V.; Raats, J.; Skarlos, D.; Newstat, B.; Roychowdhury, D.; Paoletti, P.; Oliva, C.; Rubin, S.; Stein, S.; Geyer, C. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat., 2008, Jan, 11.
110. Geyer, C.; Forster, J.; Lindquist, D.; Chan, S.; Romieu, C.; Pienkowski, T.; Jagiello-Gruszfeld, A.; Crown, J.; Chan, A.; Kaufman, B.; Skarlos, D.; Campone, M.; Davidson, N.; Berger, M.; Oliva, C.; Rubin, S.; Stein, S.; Cameron, D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N. Engl. J. Med., 2006, 28 2733.
111. Storniolo, A.M.; Pegram, M.D.; Overmoyer, B.; Silverman, P.; Peacock, N.W.; Jones, S.F.; Loftiss, J.; Arya, N.; Koch, K.M.; Paul, E.; Pandite, L.; Fleming, R.A.; Lebowitz, P.F.; Ho P.T.; Burris, H.A. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. Breast Cancer J. Clin. Oncol., 2008, 26, 3317.
112. Frödin, M.; Gammeltoft, S. Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in signal transduction. Mol. Cell Endocrinol., 1999, 151, 65.
113. Nebreda, A.R.; Gavin, A.C. Perspectives: signal transduction. Cell survival demands some Rsk. Science, 1999, 286, 1309.
114. Yntema, H.G.; van den Helm, B.; Kissing, J.; van Duijnhoven, G.; Poppelaars, F.; Chelly, J.; Moraine, C.; Fryns, J.P.; Hamel, B.C.; Heilbronner, H.; Pander, H.J.; Brunner, H.G.; Ropers, H.H.; Cremers, F.P.; van Bokhoven, H. A novel ribosomal S6-kinase (RSK4; RPS6KA6) is commonly deleted in patients with complex X-linked mental retardation. Genomics, 1999, 62, 332.
115. Smith, J.A.; Maloney, D.J.; Hecht, S.M.; Lannigan, D.A. Structural basis for the activity of the RSK-specific inhibitor, SL0101. Bioorg. Med. Chem., 2007, 15, 5018.
116. Smith, J.A.; Poteet-Smith, C.E.; Xu, Y.; Errington, T.M.; Hecht, S.M.; Lannigan, D.A. Identification of the first specific inhibitor of p90 ribosomal S6 kinase (RSK) reveals an unexpected role for RSK in cancer cell proliferation. Cancer Res., 2005, 65, 1027.
117. Clark, D.E.; Errington, T.M.; Smith, J.A.; Frierson, H.F.; Weber, M.J.; Lannigan, D.A. The serine/threonine protein kinase, p90 ribosomal S6 kinase, is an important regulator of prostate cancer cell proliferation. Cancer Res., 2005, 65, 3108.
118. Friedrich, I.; Shir, A.; Klein, S.; Levitzki, A. RNA molecules as anti-cancer agents. Semin. Cancer Biol., 2004, 14, 223.
119. Reed, J.C.; Cuddy, M.; Haldar, S.; Croce, C.; Nowell, P.; Makover, D.; Bradley, K. BCL2-mediated tumorigenicity of a human Tlymphoid cell line: synergy with MYC and inhibition by BCL2 antisense. Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 3660.
120. Zhang, X.; Chen, Z.; Chen, Y.; Tong, T. Delivering antisense telomerase RNA by a hybrid adenovirus/adeno-associated virus significantly suppresses the malignant phenotype and enhances cell apoptosis of human breast cancer cells. Oncogene, 2003, 22, 2405.
121. Scotlandi, K.; Avnet, S.; Benini, S.; Manara, M.C.; Serra, M.; Cerisano, V.; Perdichizzi, S.; Lollini, P.L.; De Giovanni, C.; Landuzzi, L.; Picci, P. Expression of an IGF-I receptor dominant negative mutant induces apoptosis, inhibits tumorigenesis and enhances chemosensitivity in Ewing's sarcoma cells. Int. J. Cancer, 2002, 101, 11.
122. Belletti, B.; Ferraro, P.; Arra, C.; Baldassarre, G.; Bruni, P.; Staibano, S.; De Rosa, G.; Salvatore, G.; Fusco, A.; Persico, M.G.; Viglietto, G. Modulation of in vivo growth of thyroid tumorderived cell lines by sense and antisense vascular endothelial growth factor gene. Oncogene, 1999, 18, 4860.
123. Fire, A.; Xu, S.; Montgomery, M.K.; Kostas, S.A.; Driver, S.E.; Mello, C.C. Potent and specific genetic interference by doublestranded RNA in Caenorhabditis elegans. Nature, 1998, 391, 806.
124. Damm-Welk, C.; Fuchs, U.; Wossmann, W.; Borkhardt, A. Targeting oncogenic fusion genes in leukemias and lymphomas by RNA interference. Semin. Cancer Biol., 2003, 13, 283.
125. Brummelkamp, T.R.; Bernards, R.; Agami, R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell, 2002, 2 243.